Doctors and patients openly shared thoughts online about the Avandia diabetes drug as early as 2005 - and a clear shift in sentiment could be seen over the years.
Wayne, PA (PRWEB) September 1, 2010
Wool.labs, a business intelligence company driven by social cognition technology, has published the "Patient Social Intelligence Report" through SmartBrief, showing a significant change in sentiment among patients who were prescribed Avandia, a medication for which pharmaceutical giant GlaxoSmithKline has battled ongoing questions about its risks, questioning the drug's side effects via social media long before its safety issues came to light in the mainstream media.
The study leveraged Wool.labs’ unique WebDig technology to track every conversation accessible on the internet to determine the prevalence of comments patients and physicians made about the potential risks and concerns regarding Avandia. It found that there was a strong base of conversations to draw from that extended back several years before the safety issues came to light in the mainstream media.
Signals appeared as early as 2005 that patients needed acknowledgment and more information about what they were experiencing. Negative sentiment rose significantly from 2004 to 2005 and has continued to grow since, as patients stop discussing the benefits they enjoyed from Avandia and start to discuss concerns. From 2006 until the present, conversation intensity and sentiment degrade further as patient anger increases over concerns of heart problems and a lack of clear and understandable information from doctors, GSK, or the FDA.
Wool.labs created a way to measure sentiment online, in order to provide a more in depth analysis of how products like Avandia are being regarded on the market. “We developed our Sentiment Index to provide a consistent, repeatable and trackable method to see how sentiment changes over time related to a particular topic.” said Michele Bennett, Chief Operating Officer of Wool.labs. “Since WebDig is able to measure all of the conversations on the Internet, the only tool of its kind, we have an indicator that is comprehensive yet easy to use as part of other quantitative analyses. An industry expert develops reports from the data in the WebDig dashboard and we make both the dashboard and the report available to our clients."
Scott Reese, CEO of Wool.labs sums up the significance of the report's findings: “The results from this Avandia study, as well as many others we have done, are eye-opening in their clarity and predictive accuracy. While some ‘monitor’ their brands or company, we see the opportunity to understand attitudes and address key business issues. User generated content in social media is an incredibly rich source of unstructured data and is full of insights. The key is to leverage technology that can make sense of it and bring those insights forward. That’s what we do.”
The Patient Social Intelligence Report is a series of retrospective and predictive analyses created by Wool.labs that digs into the hottest topics in the Healthcare and Pharmaceutical industries across a variety of diseases and conditions to understand the sentiment, behavior and beliefs of patients and the impact on business of healthcare.
Wool.labs is a new breed of business intelligence software provider. Our proprietary technology solutions help enterprise clients understand and solve complex business challenges through Social Cognition. We dig deep into dialogue data to uncover core insights and emerging trends to inform strategy, change behavior and drive new business opportunities in a way that is unmatched in the industry.
For more information, visit http://woollabs.com/avandia_pr.aspx